Biogen Inc. (BIIB): Adam Koppel , EVP, Strategy and Bus. Dev. of Biogen Inc. sold 555 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 7, 2016 to the Securities and Exchange Commission. The shares were sold at $290.00 per share for a total value of $160,950.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 6, 2016, George A Scangos (Chief Executive Officer) sold 842 shares at $290.00 per share price.On Apr 7, 2016, Adam Koppel (EVP, Strategy and Bus. Dev.) sold 102 shares at $275.00 per share price.Also, On Feb 26, 2016, Alfred Sandrock (EVP CMO Neuro & Neurodegenerat) sold 183 shares at $261.90 per share price.On Dec 3, 2015, Adriana Karaboutis (EVP, Tech. and Bus. Solutions) sold 48 shares at $289.14 per share price.
Biogen Inc: On Friday, Jun 3, 2016 heightened volatility was witnessed in Biogen Inc which led to swings in the share price. The shares opened for trading at $289.51 and hit $292.69 on the upside , eventually ending the session at $290.23, with a gain of 0.17% or 0.5 points. The heightened volatility saw the trading volume jump to 14,72,999 shares. The 52-week high of the share price is $420.99 and the company has a market cap of $63,575 M . The 52-week low of the share price is at $242.07.
Company has been under the radar of several Street Analysts.Biogen Inc is Downgraded by Citigroup to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Jun 7, 2016.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.